Cargando…

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

PURPOSE: This post-hoc analysis examined whether age modified the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH), using pooled data from four 78-week placebo-controlled phase 3 trials (ODYSSEY FH I, FH II, LONG TERM, and HIGH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ginsberg, Henry N., Tuomilehto, Jaakko, Hovingh, G. Kees, Cariou, Bertrand, Santos, Raul D., Brown, Alan S., Sanganalmath, Santosh K., Koren, Andrew, Thompson, Desmond, Raal, Frederick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433806/ https://www.ncbi.nlm.nih.gov/pubmed/30734207 http://dx.doi.org/10.1007/s10557-019-06852-6

Ejemplares similares

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
por: Bays, Harold E., et al.
Publicado: (2018)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia
por: Raal, Frederick J., et al.
Publicado: (2016)

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials
por: Ginsberg, Henry N., et al.
Publicado: (2021)

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
por: Ganda, Om P., et al.
Publicado: (2018)

Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous ABCG5 Gene Mutations Treated with Ezetimibe and Alirocumab
por: Tanaka, Hiroki, et al.
Publicado: (2020)

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
por: Pérez de Isla, Leopoldo, et al.
Publicado: (2023)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
por: Kastelein, John J. P., et al.
Publicado: (2014)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

New Approaches in Detection and Treatment of Familial Hypercholesterolemia
por: Hartgers, Merel L., et al.
Publicado: (2015)

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
por: Ge, Xiaoyue, et al.
Publicado: (2021)

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
por: Bays, Harold E., et al.
Publicado: (2017)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
por: Stroes, Erik, et al.
Publicado: (2016)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge
por: Vuorio, Alpo, et al.
Publicado: (2021)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
por: Nam, Chang-Wook, et al.
Publicado: (2019)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
por: Dardano, Angela, et al.
Publicado: (2021)

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
por: Colhoun, Helen M, et al.
Publicado: (2014)

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
por: Bruckert, Eric, et al.
Publicado: (2022)

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
por: Vuorio, Alpo, et al.
Publicado: (2021)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy
por: Vuorio, Alpo, et al.
Publicado: (2022)

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
por: Ershova, Alexandra I., et al.
Publicado: (2016)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021)

Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association
por: Hemphill, Linda, et al.
Publicado: (2020)

Differential DNA methylation in familial hypercholesterolemia
por: Reeskamp, Laurens F., et al.
Publicado: (2020)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
por: Colhoun, Helen M., et al.
Publicado: (2020)

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
por: Vuorio, Alpo, et al.
Publicado: (2021)

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
por: Agarwala, Anandita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ktatnjc1df9gsgd3fk0upqp8o8